Panagora Asset Management Inc. Purchases 79,237 Shares of IQVIA Holdings Inc. $IQV

Panagora Asset Management Inc. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 69.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 192,780 shares of the medical research company’s stock after purchasing an additional 79,237 shares during the period. Panagora Asset Management Inc. owned approximately 0.11% of IQVIA worth $43,455,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $27,000. Activest Wealth Management raised its stake in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares in the last quarter. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $35,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IQV shares. Royal Bank Of Canada started coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Finally, Truist Financial cut their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $224.13.

IQVIA Price Performance

NYSE IQV opened at $178.07 on Tuesday. The firm has a market capitalization of $29.72 billion, a P/E ratio of 22.07, a P/E/G ratio of 1.56 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The firm’s fifty day simple moving average is $173.65 and its two-hundred day simple moving average is $193.06.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.